Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Net Cash Flow came in at $9.2 million in Q1 2026, up 197.32% YoY from $3.1 million in Q1 2025, and up 182.18% on a QoQ basis from -$11.2 million in Q4 2025.
Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Net Cash Flow data on file, last reported at $9.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 197.32% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (down 769.78% YoY) and the FY2025 annual result came in at -$118.6 million, down 193.3% from the prior year.
- Net Cash Flow climbed to $9.2 million in Q1 2026, from -$11.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $102.8 million in Q1 2024 to a low of -$82.7 million in Q2 2025.
- A 5-year average of -$1.7 million and a median of -$9.5 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 1444.51% — and 2024, when it surged 2784.25%.
- Tracing AVTX's Net Cash Flow over 5 years: stood at -$3.9 million in 2022, then climbed by 28.33% to -$2.8 million in 2023, then surged by 2004.7% to $52.7 million in 2024, then plunged by 121.27% to -$11.2 million in 2025, then soared by 182.18% to $9.2 million in 2026.
- The last three Net Cash Flow figures came in at $9.2 million (Q1 2026), -$11.2 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 60.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.28 Mn |
| Jun 30, 2026 | 60.28 Mn |
| Mar 31, 2026 | 9.20 Mn |
| Mar 31, 2026 | 9.20 Mn |
| Dec 31, 2025 | -11.20 Mn |
| Dec 31, 2025 | -11.20 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Jun 30, 2025 | -82.67 Mn |
| Jun 30, 2025 | -82.67 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | 52.67 Mn |
| Dec 31, 2024 | 52.67 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.76 Mn |
| Jun 30, 2024 | -16.76 Mn |
| Mar 31, 2024 | 102.77 Mn |
| Mar 31, 2024 | 102.77 Mn |